{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:56Z","timestamp":1786988036047,"version":"build-2736575974"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114000","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T23:10:46Z","timestamp":1710285046000},"page":"114000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)"],"prefix":"10.1016","volume":"202","author":[{"given":"Gael S.","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5694-4022","authenticated-orcid":false,"given":"Loic","family":"Verlingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4588-0585","authenticated-orcid":false,"given":"Matthieu","family":"Sarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3286-8608","authenticated-orcid":false,"given":"Emmanuel","family":"Boleslawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Boudjema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bretagne-Bignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Camus-Duboc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4420-8340","authenticated-orcid":false,"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"De Baere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Dromain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Gelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Laurent-Croise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Meilleroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-7477","authenticated-orcid":false,"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3939","authenticated-orcid":false,"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rosmorduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Sa","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Soubrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2282-0101","authenticated-orcid":false,"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-4706","authenticated-orcid":false,"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114000_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2024.114000_bib3","article-title":"Estimations nationales de l\u2032incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 - Tumeurs solides: \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim","author":"Defossez","year":"2019","journal-title":"Synth\u00e8se"},{"key":"10.1016\/j.ejca.2024.114000_bib4","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2024.114000_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/1097-0142(20000815)89:4<757::AID-CNCR6>3.0.CO;2-H","article-title":"Trends in incidence and management of gallbladder carcinoma: a population-based study in France","volume":"89","author":"Manfredi","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jhep.2010.06.039","article-title":"Trends in the incidence and management of biliary tract cancer: a French population-based study","volume":"54","author":"Lepage","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2024.114000_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2024.114000_bib8","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.30074","article-title":"Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study","volume":"122","author":"Flemming","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib9","article-title":"Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis","volume":"15","author":"Neuzillet","year":"2022","journal-title":"Lancet Reg Health \u2013 Eur"},{"key":"10.1016\/j.ejca.2024.114000_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.114000_bib11","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11605-013-2215-4","article-title":"A simple system to predict perihilar cholangiocarcinoma resectability","volume":"17","author":"Boudjema","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archsurg.1993.01420200045008","article-title":"Outcomes after curative resections of cholangiocarcinoma","volume":"128","author":"Nagorney","year":"1993","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1245\/ASO.2004.03.011","article-title":"Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer","volume":"11","author":"Hawkins","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1259\/bjr\/88405305","article-title":"Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis","volume":"85","author":"Ruys","year":"2012","journal-title":"Br J Radio"},{"key":"10.1016\/j.ejca.2024.114000_bib16","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00261-020-02559-7","article-title":"Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings","volume":"45","author":"Saleh","year":"2020","journal-title":"Abdom Radio (NY)"},{"key":"10.1016\/j.ejca.2024.114000_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/13651820801992617","article-title":"Staging cholangiocarcinoma by imaging studies","volume":"10","author":"Vilgrain","year":"2008","journal-title":"HPB (Oxf)"},{"key":"10.1016\/j.ejca.2024.114000_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gie.2013.12.031","article-title":"EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study","volume":"80","author":"Weilert","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib19","doi-asserted-by":"crossref","first-page":"E769","DOI":"10.1055\/s-0043-123186","article-title":"EUS-FNA versus ERCP for tissue diagnosis of suspect malignant biliary strictures: a prospective comparative study","volume":"6","author":"Moura","year":"2018","journal-title":"Endosc Int Open"},{"key":"10.1016\/j.ejca.2024.114000_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.gie.2014.09.017","article-title":"Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2169\/internalmedicine.1551-18","article-title":"Investigation of Factors Affecting the Sensitivity of Bile Duct Brush Cytology","volume":"58","author":"Kobayashi","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.ejca.2024.114000_bib23","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1055\/s-0042-108854","article-title":"Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography","volume":"04","author":"Roth","year":"2016","journal-title":"Endosc Int Open"},{"key":"10.1016\/j.ejca.2024.114000_bib24","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1007\/s10620-021-07138-4","article-title":"Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis","volume":"67","author":"Yoon","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejca.2024.114000_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/flgastro-2018-100985","article-title":"Impact of peroral cholangioscopy on the management of indeterminate biliary conditions: a multicentre prospective trial","volume":"10","author":"Prat","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.ejca.2024.114000_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000001008","article-title":"Digital Pancreaticocholangioscopy for Mapping of Pancreaticobiliary Neoplasia: Can We Alter the Surgical Resection Margin?","volume":"53","author":"Tyberg","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ejca.2024.114000_bib27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.gie.2019.11.025","article-title":"Digital single-operator peroral cholangioscopy-guided biopsy sampling versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized, multicenter trial (with video)","volume":"91","author":"Gerges","year":"2020","journal-title":"Gastrointest Endosc"},{"issue":"No 5","key":"10.1016\/j.ejca.2024.114000_bib28","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-140","article-title":"Immunoglobulin (Ig) G4-related sclerosing cholangitis in patients resected for presumed perihilar cholangiocarcinoma: a 10-year experience","volume":"Vol 9","author":"Feng","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2024.114000_bib29","article-title":"IgG4-Associated Cholangitis in Patients Resected for Presumed Perihilar Cholangiocarcinoma: a 30-Year Tertiary care Experience","volume":"113","author":"Roos","year":"2018","journal-title":"J Am Coll Gastroenterol | ACG"},{"key":"10.1016\/j.ejca.2024.114000_bib30","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","article-title":"The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis","volume":"50","author":"Levy","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejca.2024.114000_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0016-5085(95)90462-X","article-title":"Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis","volume":"108","author":"Ramage","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2024.114000_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000000957","article-title":"C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis","volume":"41","author":"Yeh","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2024.114000_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114000_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/gut.52.4.592","article-title":"Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden","volume":"52","author":"Hemminki","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2024.114000_bib35","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","article-title":"Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma","volume":"27","author":"Riby","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib37","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00268-011-1134-3","article-title":"Incidental gallbladder cancer by the AFC-GBC-2009 Study Group","volume":"35","author":"Fuks","year":"2011","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib38","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","article-title":"Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the usa: facility type is associated with margin status, use of lymphadenectomy and overall survival","volume":"43","author":"Wu","year":"2019","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib39","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","article-title":"Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment","volume":"29","author":"de Jong","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1245\/s10434-007-9627-x","article-title":"Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study","volume":"15","author":"Tan","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/bjs.10399","article-title":"Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma","volume":"104","author":"Bird","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib42","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1245\/s10434-015-4472-9","article-title":"The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma","volume":"22","author":"Spolverato","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","article-title":"Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma","volume":"78","author":"Sposito","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2024.114000_bib44","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","article-title":"Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment","volume":"29","author":"de Jong","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","author":"Weber","year":"2015","journal-title":"HPB (Oxf)"},{"key":"10.1016\/j.ejca.2024.114000_bib46","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00000658-199809000-00011","article-title":"Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system","volume":"228","author":"Burke","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00000658-200103000-00013","article-title":"Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection","volume":"233","author":"Kitagawa","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00000658-199912000-00010","article-title":"Extended resections for hilar cholangiocarcinoma","volume":"230","author":"Neuhaus","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000004322","article-title":"Combined Vascular Resection for Locally Advanced Perihilar Cholangiocarcinoma","volume":"275","author":"Mizuno","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.suc.2013.12.004","article-title":"Distal cholangiocarcinoma","volume":"94","author":"Dickson","year":"2014","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ejca.2024.114000_bib53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.2930500314","article-title":"Long- and short-term survivors after pancreatoduodenectomy for ampullary carcinoma","volume":"50","author":"Yamaguchi","year":"1992","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00000658-199204000-00004","article-title":"Inapparent carcinoma of the gallbladder. An appraisal of a radical second operation after simple cholecystectomy","volume":"215","author":"Shirai","year":"1992","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2168.2001.01749.x","article-title":"Early gallbladder carcinoma does not warrant radical resection","volume":"88","author":"Wakai","year":"2001","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib56","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00268-002-6609-9","article-title":"Completion radical surgery after cholecystectomy for accidentally undiagnosed gallbladder carcinoma","volume":"27","author":"Toyonaga","year":"2003","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00268-003-7080-y","article-title":"Appraisal of surgical treatment for pT2 gallbladder carcinomas","volume":"28","author":"Suzuki","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib58","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00464-011-2044-z","article-title":"The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry","volume":"26","author":"Goetze","year":"2012","journal-title":"Surg Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.sla.0000154118.07704.ef","article-title":"An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center","volume":"241","author":"Dixon","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib60","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.gassur.2006.03.006","article-title":"Prognostic significance of the number of positive lymph nodes in gallbladder cancer","volume":"10","author":"Endo","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib61","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2168.2000.01384.x","article-title":"Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma","volume":"87","author":"Kondo","year":"2000","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000000728","article-title":"Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study","volume":"261","author":"Shindoh","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib63","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1245\/s10434-014-4300-7","article-title":"Surgical strategy for T2 gallbladder cancer according to tumor location","volume":"22","author":"Lee","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib64","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00268-014-2864-9","article-title":"Surgical treatment of incidental gallbladder cancer discovered during or following laparoscopic cholecystectomy","volume":"39","author":"Tian","year":"2015","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib65","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00268-009-0163-7","article-title":"Use of retrieval bags in incidental gallbladder cancer cases","volume":"33","author":"Goetze","year":"2009","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/SLA.0b013e318154bf5d","article-title":"Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry","volume":"247","author":"Goetze","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib67","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jso.20535","article-title":"Surgical strategies in patients with gallbladder cancer: nihilism to optimism","volume":"93","author":"Sikora","year":"2006","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib68","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1245\/s10434-014-3527-7","article-title":"Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea","volume":"21","author":"Lee","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01658725","article-title":"Radical operations for carcinoma of the gallbladder: Present status in Japan","volume":"15","author":"Ogura","year":"1991","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib70","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/1097-0142(19920101)69:1<60::AID-CNCR2820690112>3.0.CO;2-N","article-title":"Gallbladder cancer in Chile. A report on 54 potentially resectable tumors","volume":"69","author":"de Aretxabala","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.114000_bib72","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2024.114000_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib74","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2024.114000_bib75","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib76","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4019","article-title":"Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP)","volume":"40","author":"Yoo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114000_bib79","article-title":"Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2024.114000_bib80","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib81","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13651820801992567","article-title":"Guidelines for palliative surgery of cholangiocarcinoma","volume":"10","author":"Witzigmann","year":"2008","journal-title":"HPB"},{"key":"10.1016\/j.ejca.2024.114000_bib83","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.gie.2010.06.040","article-title":"Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment","volume":"72","author":"Vienne","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib84","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.gie.2016.12.023","article-title":"Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: a systematic review and meta-analysis","volume":"85","author":"Sharaiha","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1756283X17702614","article-title":"Is EUS-guided drainage a suitable alternative technique in case of proximal biliary obstruction?","volume":"10","author":"Moryoussef","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.ejca.2024.114000_bib86","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.gie.2015.10.035","article-title":"Self-expandable metal stents versus plastic stents for malignant biliary obstruction","volume":"83","author":"Almadi","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib87","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1055\/a-0659-9864","article-title":"Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017","volume":"50","author":"Dumonceau","year":"2018","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2024.114000_bib88","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.gie.2018.04.2332","article-title":"Efficacy and safety of endobiliary radiofrequency ablation for the eradication of residual neoplasia after endoscopic papillectomy: a multicenter prospective study","volume":"88","author":"Camus","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib89","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s00464-015-4322-7","article-title":"Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma","volume":"30","author":"Laqui\u00e8re","year":"2016","journal-title":"Surg Endosc"},{"key":"10.1016\/j.ejca.2024.114000_bib90","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","article-title":"Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive 9902 phase II randomised study","volume":"50","author":"Phelip","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib91","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib93","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib94","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2011.05.016","article-title":"Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience","volume":"99","author":"Polistina","year":"2011","journal-title":"Radio Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-717X-7-67","article-title":"Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma","volume":"7","author":"Barney","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib96","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s12885-017-3788-1","article-title":"Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"17","author":"Gkika","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib97","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","article-title":"Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin","volume":"29","author":"Martin","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib98","unstructured":"Edeline J., Bridgewater J., Campillo-Gimenez B., Neveu E., Phelip J.-M., Neuzillet C., et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials. Hepatology 9900."},{"key":"10.1016\/j.ejca.2024.114000_bib99","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2024.114000_bib100","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/0284186X.2012.682628","article-title":"Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma","volume":"51","author":"Kang","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib101","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-0040-1721216","article-title":"Role of maintenance gemcitabine in advanced carcinoma gallbladder","volume":"9","author":"Sharma","year":"2020","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib103","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4143\/crt.2018.326","article-title":"Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin","volume":"51","author":"Hyung","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.114000_bib104","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase ii study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib106","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"key":"10.1016\/j.ejca.2024.114000_bib107","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib108","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib109","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114000_bib111","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib112","doi-asserted-by":"crossref","first-page":"S1462","DOI":"10.1016\/j.annonc.2022.10.114","article-title":"78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib113","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114000_bib114","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.annonc.2022.07.082","volume":"33","author":"Lamarca","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib116","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib117","first-page":"S563","article-title":"53MO Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC \u2013 AIO-HEP-0116)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib118","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib119","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study","volume":"26","author":"Santoro","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib121","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib122","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib123","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2024.114000_bib124","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41591-021-01448-w","article-title":"Limited evolution of the actionable metastatic cancer genome under therapeutic pressure","volume":"27","author":"van de Haar","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.114000_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","article-title":"Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine","volume":"179","author":"Roth","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib126","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib127","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib128","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114000_bib129","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib130","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib131","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114000_bib132","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib133","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2024.114000_bib134","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib135","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF\/FGFR Aberrations: A Phase I Dose-Expansion Study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114000_bib136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib137","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib138","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2024.114000_bib139","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.annonc.2023.09.1388","article-title":"95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory\/relapsed cholangiocarcinoma","volume":"34","author":"Javle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib140","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib141","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib142","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2024.114000_bib143","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib144","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","author":"Nakamura","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4089","article-title":"Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Na\u00efve Human Epidermal Growth Factor Receptor 2\u2013Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)","author":"Ostwal","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib147","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2021.1896703","article-title":"Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers","volume":"30","author":"Boil\u00e8ve","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejca.2024.114000_bib148","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2024.114000_bib149","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib150","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib151","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114000_bib152","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2024.114000_bib153","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib154","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"issue":"No 5","key":"10.1016\/j.ejca.2024.114000_bib155","doi-asserted-by":"crossref","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"Vol 7","author":"Jain","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib156","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib157","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.114000_bib158","first-page":"0","article-title":"Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies","author":"Salem","year":"2021","journal-title":"ESMO Gastrointest Congr"},{"key":"10.1016\/j.ejca.2024.114000_bib159","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.36_suppl.425082","article-title":"KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Pant","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114000_bib160","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114000_bib161","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.519","article-title":"KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation","volume":"40","author":"Bekaii-Saab","year":"2022","journal-title":"JCO"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:10:21Z","timestamp":1727395821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":161,"alternative-id":["S0959804924001564"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114000","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114000"}}